Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04843748
Other study ID # HTF-01
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 18, 2018
Est. completion date January 6, 2021

Study information

Verified date March 2021
Source Hanita Lenses
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Hanita Lenses Trifocal IOL, SeeLens AFR (Intensity IOL).Prospective, single-arm single-center, open-label study.


Description:

Device: Hanita Lenses Trifocal IOL, SeeLens AFR (Intensity IOL). Indication studied: The Hanita Lenses Trifocal IOL is intended for implantation in the capsular bag in the posterior chamber in order to replace the crystalline lens of the eye to attain visual correction of aphakia in adult patients in whom a cataractous lens has been removed, who desire improved uncorrected vision, useful near and intermediate visual functions, and reduced spectacle dependence. Study description: This study is a prospective, single-arm single-center, open-label study.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date January 6, 2021
Est. primary completion date January 6, 2021
Accepts healthy volunteers No
Gender All
Age group 45 Years to 75 Years
Eligibility Inclusion Criteria: - Age over 45 years and under 75 years. - Patients with bilateral age-related cataracts, require bilateral cataract phacoemulsification combined Intraocular Lens implantation; - Patients with an axial length of 22-24.5mm. - Normal corneas with less than 0.75D of regular corneal astigmatism. - Post-operative best-corrected visual acuity projected to be 0.3 logMAR or lower. - Patient motivated for trifocal IOL after screening by the surgeon. - Fundus visualization is possible. - Absence of retinal or optic nerve diseases - Signed informed consent Exclusion Criteria: - Previous ocular/corneal surgery that may affect refraction accuracy or visual acuity. - Capsule or zonular abnormalities that may affect postoperative centration or tilt of the lens (e.g. pseudoexfoliation syndrome, chronic Uveitis, Marfan's syndrome) - History or evidence of any ocular disease that may affect visual acuity (i.e. uncontrolled glaucoma, ocular injury, corneal pathologies, retinal pathologies in general and macular pathologies in particular, diabetic retinopathy, uveitis, aniridia or iris atrophy, vitreous pathologies (patients with vitreous separation or floaters can be included). - Rubella cataract. - Amblyopia - Any other ocular condition that may predispose a subject to future complications or contraindicate implantation of the trifocal lens. - Pupil abnormalities (non-reactive, tonic pupils, abnormally shaped pupils, or pupils that do not dilate at least 3.5 mm under mesopic/scotopic conditions) - Patients with pupil diameter greater than 4mm in photopic conditions. - Pregnant, lactating or planning to become pregnant during the course of the trial. - Allergy or intolerance to required study medications (including antibiotic). - Subjects participating in a concurrent clinical trial or if they have participated in an ophthalmology clinical trial within the last 30 days. - Traumatic cataract.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
cataract surgery and intraocular lens implantation - both eyes
cataract surgery and intraocular lens implantation for both eyes

Locations

Country Name City State
Israel MeirMC Kfar Saba

Sponsors (1)

Lead Sponsor Collaborator
Hanita Lenses

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Other OCULAR AND INTRAOCULAR BIOMETRICAL MEASUREMENTS Patients will be examined pre operatively for inclusion and exclusion criteria as well as at the post-operative follow ups for the measurements specified in the flow chart (Section 8.12). These include a validated biometry (Tomey AO-2000, IOL-Master, Lenstar), corneal topography, tomography (optional, performed in accordance with investigator's discretion, retinal OCT, tonometry, slit lamp examination and fundoscopy. pre- op
Other Slit Lamp Exam The slit lamp exam will include the measurement of aqueous cell and flare, and the measurement of corneal edema by a standard grading system. It will also include an evaluation for the presence of pupillary irregularities, iris atrophy and pigment dispersion.
For the evaluation of aqueous cells and flare, use a slit lamp beam 0.3 mm wide and 1 mm high, and use the following grading:
Cells none (0) = no cells seen trace (+1) = 1-5 cells seen mild (+2) = 6-15 cells seen moderate (+3) = 16-30 cells seen severe (+4) = > 30 cells seen
Flare none (0) = No Tyndall effect trace (+1) = Tyndall effect barely discernible mild (+2) = Tyndall beam in anterior chamber is mildly intense moderate (+3) = Tyndall beam in anterior chamber is moderately intense severe (+4) = Tyndall beam is severely intense. The aqueous has a white and milky appearance.
90-110 days post op
Other VISUAL ACUITY Will be measured using an ETDRS chart or PV numbers for distance and PV Numbers Near Vision Card (Precision Vision) for near (40cm) and intermediate distances (80cm). All results will be expressed in logMAR. Visual acuity will be measured in photopic conditions. Monocular BCVA will be measured under mesopic conditions in the follow up of one and three months. NOTE: All charts used should be calibrated to the specific distance to be used during the testing. For example, if the testing distance is 4m, the chart should be calibrated to that distance. 90-110 days post op
Primary Binocular visual acuity for far, intermediate and near distance after Trifocal IOL implantation Binocular visual acuity for far, intermediate and near distance after Trifocal IOL implantation 90-110 days post op
Secondary Defocus Curve Will be obtained using an ETDRS chart or PV numbers. Patient's pupil diameter will be evaluated.
In the statistical stage patients will be categorized according to smaller than 2.5mm, between 2.5 and 4.5mm and above 4.5mm for mesopic and photopic conditions.
The test will be performed using a phoropter to create defocus in 0.5D increments, starting from 1D to -4D relative to emmetropia so that the patient will be corrected for far vision.
90-110 days post op
Secondary Contrast Sensitivity Will be evaluated using a sine wave gratings chart (FACT) at mesopic and photopic conditions. Measurements will be performed with optimal refractive correction.
Luminance for photopic conditions will be 85cd/m² and 5cd/m² for mesopic conditions. Small deviations are allowed. The working interval for photopic conditions is 75-95cd/m² and for mesopic conditions is 5-15cd/m².
Luminance for photopic and mesopic conditions will be monitored using Illuminance meter and documented. Results will be expressed as values.
90-110 days post op
Secondary patient satisfaction Subjective evaluation will be performed using the modified VF-14 questionnaire for quality of life, in addition to satisfaction questionnaire. 90-110 days post op
See also
  Status Clinical Trial Phase
Completed NCT04685538 - Chloroprocaine 3% Gel Eye Drop as Topical Anestheticsin Phacoemulsification. Phase 3
Recruiting NCT06060041 - IC-8 Apthera IOL New Enrollment Post Approval Study
Recruiting NCT05518539 - Evaluation of Quality of Vision and Visual Outcomes With Bilateral Implantation of the Clareon PanOptix Intraocular Lens
Recruiting NCT05271942 - Tilt and Tumble vs Divide and Conquer - a Unique Comparison of the Two Cataract Surgery Methods N/A
Active, not recruiting NCT04778501 - PMCF Study on Monofocal Toric IOL (PODEYE TORIC) in Asia N/A
Completed NCT05062564 - Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye N/A
Completed NCT03751033 - Influence of DisCoVisc Ophthalmic Viscosurgical Device (OVD) on Intraoperative Aberrometry Readings N/A
Completed NCT02529488 - Investigation of AcrySof® IQ PanOptix™ Presbyopia-Correcting Intraocular Lens (IOL) Model TFNT00 N/A
Completed NCT04539548 - A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract Phase 3
Completed NCT03740659 - Evaluation Of Aqueous Humor Of Levofloxacin-Dexamethasone Eye Drops And Of Its Components In Patients Undergoing Cataract Surgery Phase 2
Completed NCT03494257 - Effect of Fixed Brinzolamide-brimonidine Combination on Intraocular Pressure After Phacoemulsification N/A
Completed NCT05119127 - Rotational Stability of Acrysof IQ Vivity Extended Vision Toric IOL and Refractive Visual Outcome. N/A
Active, not recruiting NCT04271709 - Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT) N/A
Recruiting NCT03713268 - Intraoperative OCT Guidance of Intraocular Surgery II
Completed NCT03739528 - Levo-Dexa vs. Tobra+Dexa for Prevention and Treatment of Inflammation and Prevention of Infection in Cataract Surgery Phase 3
Completed NCT02888210 - A Study Assessing Safety and Efficacy of MD-15 Intraocular Lens in Patients With Aphakic Eye After Cataract Surgery Phase 3
Completed NCT03356847 - Evaluation of the Rotational Stability of the Monofocal SISA Implant Following Cataract Surgery N/A
Completed NCT04332640 - Clinical Evaluation of the Next Generation Phaco System N/A
Recruiting NCT03638726 - Subconjunctival Atropine and Intracameral Epinephrine for Pupil Dilation in Phacoemulsification Phase 4
Completed NCT03050697 - Evaluation of the Safety and Performance of the HARMONI® Toric Lens N/A